Lurbinectedin is a chemotherapy drug that has shown promising results in treating small cell lung cancer (SCLC). It works by inhibiting RNA polymerase II, a protein that is essential for the transcription of DNA into RNA. This inhibition leads to the death of cancer cells [1].

Immunotherapy, on the other hand, is a type of cancer treatment that boosts the body's immune system to fight cancer. It works by using drugs that target specific proteins on cancer cells or by using genetically engineered immune cells to attack cancer cells [2].

A clinical trial (NCT04358237) is currently underway to investigate the safety and efficacy of combining lurbinectedin and pembrolizumab, an immunotherapy drug, in patients with relapsed SCLC [2]. Preliminary results from this trial have shown promising activity of the combination [3].

However, there are potential risks associated with combining lurbinectedin and immunotherapy. One concern is that lurbinectedin may suppress the immune system, which could reduce the effectiveness of immunotherapy [1]. Additionally, combining chemotherapy and immunotherapy can increase the risk of side effects, such as fatigue, nausea, and diarrhea [2].

In conclusion, while the combination of lurbinectedin and immunotherapy has shown promising results in treating SCLC, there are potential risks associated with this treatment approach. Further research is needed to fully understand the safety and efficacy of this combination therapy.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.clinicaltrials.gov/ct2/show/NCT04358237
[3] https://www.cancernetwork.com/view/antonio-calles-md-highlights-promising-preliminary-activity-of-lurbinectedin-and-pembrolizumab-in-relapsed-sclc